Over the past decade, China's exports of basic pharmaceutical products and pharmaceutical preparations to Taiwan have seen fluctuating trends. After some initial volatility, there was notable growth in 2017, followed by gradual increases until a peak in 2021. A slight dip occurred in 2022, but exports recovered in 2023, valuing at $288.43 million, a 2.71% year-on-year increase. The compound annual growth rate (CAGR) over the past five years stands at 3%. Future projections indicate a steady but modest growth rate with a forecast CAGR of 1.79% over the next five years.
Future trends to watch for include:
- Changes in Taiwan's regulatory environment impacting import volumes
- Advancements in pharmaceutical technology and innovation driving demand
- Potential shifts in geopolitical relations affecting trade policies
- Global health crises or pandemics influencing the export volumes
- Rising competition from other pharmaceutical exporting nations
